• IP Group: Portfolio Company Istesso's MBS2320 Gets FDA Fast Track And Orphan Drug Designation

    Source: NASDAQ US Markets / 05 Dec 2022 01:33:07   America/Chicago

    (RTTNews) - IP Group plc (IPO.L), a developer of science and technology businesses, Monday noted that its portfolio company Istesso Ltd.'s investigational metabolic reprogramming agent, MBS232, has received Fast Track and Orphan Drug designation from the U.S. Food and Drug Admini https://www.nasdaq.com/articles/ip-group:-portfolio-company-istessos-mbs2320-gets-fda-fast-track-and-orphan-drug
Share on,